Thomas King, MS MPH

SCYNEXIS, Inc.
Jersey City, New Jersey, United States

I do not have any relevant financial / non-financial relationships with any proprietary interests.

Presentation(s):

• 871 - Oral Ibrexafungerp Outcomes by Fungal Disease in Patients from an Interim Analysis of a Phase 3 Open-label Study (FURI)

  Friday, October 21, 2022
  11:15 AM - 11:30 AM US ET